Developing central nervous system and vulnerability to platinum compounds.
G Bernocchi1, M G Bottone, V M Piccolini
1Laboratorio di Biologia Cellulare e Neurobiologia, Dipartimento di Biologia Animale, Università di Pavia, Via Ferrata 1, 27100 Pavia, Italy.
Chemotherapy Research and Practice
|February 8, 2012
Summary
This study compared cisplatin (cisPt) and a new platinum compound (PtAcacDMS) for neurotoxicity during rat cerebellum development. PtAcacDMS showed lower neurotoxicity, suggesting a potentially safer alternative chemotherapy agent.
Area of Science:
- Neuroscience
- Pharmacology
- Developmental Biology
Background:
- Platinum-based chemotherapy agents like cisplatin (cisPt) are vital in cancer treatment but can cause significant neurotoxicity.
- Understanding the neurotoxic potential and reversibility of platinum compounds is crucial for developing safer anticancer drugs.
- Cisplatin's mechanism involves DNA binding, leading to both therapeutic effects and side effects.
Purpose of the Study:
- To compare the neurotoxicity of cisplatin (cisPt) with a novel platinum compound, [Pt(O,O'-acac)(γ-acac)(DMS)] (PtAcacDMS), during rat postnatal cerebellum development.
- To evaluate the effects of these platinum compounds on critical developmental events in the cerebellum, including cell proliferation, migration, and neuronal differentiation.
- To assess the potential of PtAcacDMS as a less neurotoxic alternative to cisPt.
Main Methods:
- Comparative analysis of neurotoxicity and chemoresistance of cisPt and PtAcacDMS.
- In vivo studies on rat postnatal cerebellum development, evaluating acute and late effects of drug treatments.
- Assessment of cell proliferation and death in the external granular layer, granule cell migration, and Purkinje cell dendrite growth.
Main Results:
- PtAcacDMS demonstrated lower neurotoxicity compared to cisPt in the developing rat cerebellum.
- Both acute effects (cell proliferation/death, migration) and late effects (dendrite growth) were evaluated.
- The study considered the presence of PtAcacDMS in the brain and its implications for blood-brain barrier permeability.
Conclusions:
- Data suggest that PtAcacDMS exhibits a lower neurotoxic profile than cisPt.
- PtAcacDMS warrants further investigation as a potentially safer platinum-based chemotherapeutic agent.
- Considerations regarding blood-brain barrier permeability are important when evaluating PtAcacDMS's effects in the brain.
Related Concept Videos
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:24Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
01:29Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:21Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...